A dynamic force in the fight against infectious diseases

Committed to protecting the world against dangerous and difficult-to-treat fungal pathogens.

Learn More

A ground-breaking advancement

Fungerps: our novel anti-fungal agents

The fungerps are an innovative new weapon for potential deployment against a range of serious fungal infections.

Learn More

Innovation in action

Life-Threatening Infections

We’re bringing new weapons to the fight against debilitating and life-threatening infections that pose serious challenges in hospitals.

Learn More

Serving Unmet Needs

Anti-microbial resistance threat

The increase of antifungal-resistant pathogens is reported globally. Considering the limited treatment options and often deadly outcomes of these diseases, antifungal resistance is a significant global health threat.

Learn More

Our pipeline

Our work on meaningful scientific breakthroughs has the power to change lives.

Learn More

Latest news

  • 11/06/24

    SCYNEXIS Reports Third Quarter 2024 Financial Results and Provides Corporate Update

    Read More >
  • 10/10/24

    SCYNEXIS to Participate in the 2024 Maxim Healthcare Virtual Summit

    Read More >
  • 10/03/24

    SCYNEXIS to Present Preclinical Data on Second Generation Fungerp SCY-247 at IDWeek 2024

    Read More >
  • 08/27/24

    SCYNEXIS to Participate in H. C. Wainwright 26th Annual Global Investment Conference

    Read More >
  • 08/08/24

    SCYNEXIS Reports Second Quarter 2024 Financial Results and Provides Corporate Update

    Read More >
  • 07/23/24

    SCYNEXIS to Receive $10 Million Milestone Payment from GSK Triggered by Delivery of Completed FURI, CARES and NATURE Clinical Study Reports

    Read More >
  • 05/08/24

    SCYNEXIS Reports First Quarter 2024 Financial Results and Provides Corporate Update

    Read More >
  • 04/30/24

    SCYNEXIS Presented Preclinical Data on Second Generation Fungerp SCY-247 at the Congress of the European Society of Clinical Microbiology and Infectious Diseases (ESCMID Global, Formerly ECCMID)

    Read More >
  • 04/09/24

    SCYNEXIS to Present Preclinical Data on Second Generation Fungerp SCY-247 at the 34th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID)

    Read More >
  • 03/28/24

    SCYNEXIS Reports Full Year 2023 Financial Results and Provides Corporate Update

    Read More >

View All

Interested in learning more about our products, partnership opportunities and more?

Learn More

Make a Difference

Join Our Team

Our people are on a mission to cure infectious diseases and make a real difference in the lives of people around the world. Are you up for the challenge? Discover why you should join SCYNEXIS in the fight against fungal disease.

Learn More